VEGFA and neoplasm: Bevacizumab was the first recombinant humanized murine IgG1 monoclonal antibody capable of blocking the activity of the Vascular Endothelial Growth Factor A (VEGF-A), a natural ligand that plays a pivotal role in tumor angiogenesis [35].